MedTrace Logo

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1481

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

Conditions

Interventions

DRUG

LY3305677

Administered SC. ISA specific interventions will be listed in the ISA.

DRUG

LY3841136

Administered SC. ISA specific interventions will be listed in the ISA.

DRUG

Tirzepatide

Administered SC. ISA specific interventions will be listed in the ISA.

DRUG

LY3549492

Administered orally. ISA specific interventions will be listed in the ISA.

DRUG

LY3532226

Administered SC. ISA specific interventions will be listed in the ISA.

DRUG

Placebo

Administered SC. ISA specific interventions will be listed in the ISA.

DRUG

Placebo

Administered orally. ISA specific interventions will be listed in the ISA.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-17
Primary Completion
2027-09-30
Completion
2028-02-29
FDA Drug
Yes

Countries

  • United States
  • Argentina

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06143956 on ClinicalTrials.gov